CLINICAL TRIALS PROFILE FOR ABILIFY MAINTENA KIT

All Clinical Trials for ABILIFY MAINTENA KIT

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02146547 ↗	European Long-acting Antipsychotics in Schizophrenia Trial	Completed	UMC Utrecht	Phase 4	2015-02-01	Schizophrenia is a chronic psychiatric illness with periods of remission and relapse. Patients vary in the frequency and severity of relapse, time until relapse and time in remission. Discontinuation of antipsychotic medication is by far the most important reason for relapse. A possible method to optimize medication adherence is to treat patients with long-term, depot medication rather than oral medication. However, despite its apparent "common sense" this approach has neither been universally accepted by practicing psychiatrists nor unequivocally demonstrated in clinical trials. Therefore, in this study we aim to investigate possible advantages of depot medication over oral antipsychotics in an independently designed and conducted, randomized, pragmatic trial.
NCT02472652 ↗	Aripiprazole, Abilify Maintena Collaborative Clinical Protocol	Terminated	Otsuka America Pharmaceutical	Phase 4	2015-06-01	Sexual dysfunction is highly prevalent in schizophrenic patients, affecting up to 80% of men and women. Antipsychotic induced sexual side effects may be a barrier to treatment compliance. Antipsychotics such as Risperdal Consta and Invega Sustenna are known to have higher rates of causing prolactin elevations that may be implicated in sexual dysfunction. The basic premise of this study is to identify patients who believe they have experienced sexual dysfunction on Risperdal Consta or Invega Sustenna and switch to the alternative long acting injectable antipsychotic, Abilify Maintena which tends to lower prolactin levels. Measures of sexual sexual functioning using the self rated 5 item Arizona Sexual Experience Scale (ASEX) as the primary outcome measure will be made over a 3 month period to determine if such a switch is helpful.
NCT02472652 ↗	Aripiprazole, Abilify Maintena Collaborative Clinical Protocol	Terminated	Gazda, Thomas D., M.D., PC	Phase 4	2015-06-01	Sexual dysfunction is highly prevalent in schizophrenic patients, affecting up to 80% of men and women. Antipsychotic induced sexual side effects may be a barrier to treatment compliance. Antipsychotics such as Risperdal Consta and Invega Sustenna are known to have higher rates of causing prolactin elevations that may be implicated in sexual dysfunction. The basic premise of this study is to identify patients who believe they have experienced sexual dysfunction on Risperdal Consta or Invega Sustenna and switch to the alternative long acting injectable antipsychotic, Abilify Maintena which tends to lower prolactin levels. Measures of sexual sexual functioning using the self rated 5 item Arizona Sexual Experience Scale (ASEX) as the primary outcome measure will be made over a 3 month period to determine if such a switch is helpful.
NCT02717130 ↗	Aripiprazole, Abilify Maintena Collaborative Clinical Protocol	Terminated	Burrell Behavioral Health	N/A	2016-06-08	An Open-label, Multi-center, Longitudinal, Within-subject Comparison Study to Evaluate the Effects of Aripiprazole Once Monthly in Subjects with Schizophrenia on 30-, 90-, and 180- day Re-hospitalization Rates Following Hospital Discharge Compared with Retrospective Re-hospitalization Rates while on Oral Antipsychotic Medication.
NCT02717130 ↗	Aripiprazole, Abilify Maintena Collaborative Clinical Protocol	Terminated	University of Missouri-Columbia	N/A	2016-06-08	An Open-label, Multi-center, Longitudinal, Within-subject Comparison Study to Evaluate the Effects of Aripiprazole Once Monthly in Subjects with Schizophrenia on 30-, 90-, and 180- day Re-hospitalization Rates Following Hospital Discharge Compared with Retrospective Re-hospitalization Rates while on Oral Antipsychotic Medication.
NCT02717130 ↗	Aripiprazole, Abilify Maintena Collaborative Clinical Protocol	Terminated	University of Missouri, Kansas City	N/A	2016-06-08	An Open-label, Multi-center, Longitudinal, Within-subject Comparison Study to Evaluate the Effects of Aripiprazole Once Monthly in Subjects with Schizophrenia on 30-, 90-, and 180- day Re-hospitalization Rates Following Hospital Discharge Compared with Retrospective Re-hospitalization Rates while on Oral Antipsychotic Medication.
NCT02717130 ↗	Aripiprazole, Abilify Maintena Collaborative Clinical Protocol	Terminated	Washington University School of Medicine	N/A	2016-06-08	An Open-label, Multi-center, Longitudinal, Within-subject Comparison Study to Evaluate the Effects of Aripiprazole Once Monthly in Subjects with Schizophrenia on 30-, 90-, and 180- day Re-hospitalization Rates Following Hospital Discharge Compared with Retrospective Re-hospitalization Rates while on Oral Antipsychotic Medication.

Clinical Trial Conditions for ABILIFY MAINTENA KIT

Condition Name

Condition Name for ABILIFY MAINTENA KIT
Intervention	Trials
Schizophrenia	7
Antipsychotics	1
Aripiprazole	1
Bipolar Disorder	1

Condition MeSH

Condition MeSH for ABILIFY MAINTENA KIT
Intervention	Trials
Schizophrenia	7
Disease	1
Bipolar Disorder	1

Clinical Trial Locations for ABILIFY MAINTENA KIT

Trials by Country

Trials by Country for ABILIFY MAINTENA KIT
Location	Trials
United States	7
Korea, Republic of	7
Spain	4
Germany	4
Italy	3

Trials by US State

Trials by US State for ABILIFY MAINTENA KIT
Location	Trials
Ohio	1
Texas	1
California	1
Arkansas	1
Missouri	1

Clinical Trial Progress for ABILIFY MAINTENA KIT

Clinical Trial Phase

Clinical Trial Phase for ABILIFY MAINTENA KIT
Clinical Trial Phase	Trials
Phase 4	5
Phase 1	3
N/A	1

Clinical Trial Status

Clinical Trial Status for ABILIFY MAINTENA KIT
Clinical Trial Phase	Trials
Completed	6
Terminated	2
Active, not recruiting	1

Clinical Trial Sponsors for ABILIFY MAINTENA KIT

Sponsor Name

Sponsor Name for ABILIFY MAINTENA KIT
Sponsor	Trials
Otsuka Pharmaceutical Development & Commercialization, Inc.	2
Otsuka Beijing Research Institute	2
Otsuka Pharmaceutical Co., Ltd.	1

Sponsor Type

Sponsor Type for ABILIFY MAINTENA KIT
Sponsor	Trials
Other	9
Industry	8